IDWeek 2026 Highlights: Advances in Treatments for Fungal, Bacterial, and Viral Infections
Audio narration · Coming soon
This first roundup from IDWeek 2026 highlights key developments in infectious disease treatments. Oral olorofim showed comparable effectiveness to AmBisome for invasive aspergillosis, aztreonam-avibactam remained active against rising MBL-producing CRE, pritelivir reduced hospitalizations in refractory HSV cases, and zelicapavir shortened RSV symptoms in high-risk adults.
Why this matters
PRISM scored this story 65/100 for interest.
Originally published by gnews